Lipoprotein Drug Delivery Initiative: A Translational research program employing the HDL and HDL mimetic drug delivery platform.

Date

2020

Authors

Raut, Sangram
Sabnis, Nirupama
Fudala, Rafal
Lacko, Andras G.
Saranya Conjeevaram Nagarajan, Bhavani
Dossou, Akpedie

ORCID

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Reconstituted (synthetic) lipoproteins and lipoprotein mimetics have been recognized as a superior biocompatible, targeted drug-delivery platform and thus have great potential in the treatment of a number of diseases. Our laboratory has been involved in exploiting the potential of rHDL nanoparticles (NPs) in cancer theranostics. Traditional chemotherapy is afflicted with long and short term side effects due to off target delivery of anti-cancer agents. In fact, often the side effects prove more damaging to the patients than the disease itself. Lipoprotein-based technologies could address this challenge due to their ability to selectively deliver their payload to cancer cells and tumors, via a receptor mediated mechanism. The therapeutic index (side effect profile) of a drug can thus be significantly improved by directing the selective delivery capabilities of the rHDL NPs toward tumors but not toward normal tissues. The contributions of our laboratory in facilitating the progress of this technology toward its clinical applications for the treatment of cancers are highlighted in this presentation.

Description

Keywords

Citation

Rights

License

Collections